{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:56:09Z","timestamp":1761872169303,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.clml.2022.11.010","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T10:33:50Z","timestamp":1669372430000},"page":"e190-e194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Augmented ICE in Patients With Poor-Risk Refractory and Relapsed Lymphomas"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6294-2691","authenticated-orcid":false,"given":"Sun","family":"Loo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sze Ting","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.11.010_bib0001","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.clml.2014.02.012","article-title":"Clinical efficacy and safety in relapsed\/refractory diffuse large B-cell lymphoma: a systematic literature review","volume":"14","author":"Colosia","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2 Suppl 4","key":"10.1016\/j.clml.2022.11.010_bib0002","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1053\/j.seminoncol.2004.02.016","article-title":"An update on the management of relapsed and primary refractory Hodgkin's disease","volume":"31","author":"Moskowitz","year":"2004","journal-title":"Semin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2022.11.010_bib0003","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/annonc\/mdg702","article-title":"Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma","volume":"14","author":"Zelenetz","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.11.010_bib0004","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.11.010_bib0005","article-title":"Outcomes of autologous hematopoietic cell transplantation in diffuse large B cell lymphoma refractory to firstline chemoimmunotherapy","volume":"27","author":"Bal","year":"2021","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.clml.2022.11.010_bib0006","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.010_bib0007","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","article-title":"Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma","volume":"125","author":"Sauter","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.010_bib0008","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.11.010_bib0009","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.11.010_bib0010","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbmt.2007.11.013","article-title":"Salvage therapy for relapsed\/refractory diffuse large B cell lymphoma","volume":"14","author":"Seshadri","year":"2008","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2022.11.010_bib0011","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjh.15412","article-title":"How I manage patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"182","author":"Gisselbrecht","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.11.010_bib0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2022.11.010_bib0013","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"388","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.11.010_bib0014","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.11.010_bib0015","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1365-2141.2009.08037.x","article-title":"High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging","volume":"148","author":"Moskowitz","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.11.010_bib0016","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.11.010_bib0017","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-12-3837","article-title":"Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma","volume":"102","author":"Hamlin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.010_bib0018","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.010_bib0019","article-title":"R-IVAC salvage therapy in relapsed and refractory DLBCL","volume":"37","author":"Casan","year":"2019","journal-title":"Haematology Oncol"},{"key":"10.1016\/j.clml.2022.11.010_bib0020","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.010_bib0021","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.11.010_bib0022","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1159\/000368184","article-title":"Two cases of fatal encephalopathy related to Ifosfamide: an adverse role of aprepitant?","volume":"7","author":"Sejourne","year":"2014","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.clml.2022.11.010_bib0023","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1054\/bjoc.1999.0917","article-title":"Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature","volume":"82","author":"Pelgrims","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2022.11.010_bib0024","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.coc.0000158439.02724.5a","article-title":"Evaluating risk factors for the development of ifosfamide encephalopathy","volume":"28","author":"David","year":"2005","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clml.2022.11.010_bib0025","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1200\/JCO.2008.17.5257","article-title":"Long-term evaluation of ifosfamide-related nephrotoxicity in children","volume":"27","author":"Oberlin","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:33Z","timestamp":1761871293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022017426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2152265022017426"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.11.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Augmented ICE in Patients With Poor-Risk Refractory and Relapsed Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}